Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans.

Autor:	Carter P; Department of Surgery and Cancer, Imperial College, London, UK., Alifrangis C; Department of Oncology, University College Hospital, London, UK., Cereser B; Department of Surgery and Cancer, Imperial College, London, UK., Chandrasinghe P; Department of Surgery and Cancer, Imperial College, London, UK.; Department of Surgery, University of Kelaniya, Kelaniya, Sri Lanka., Del Bel Belluz L; Department of Surgery and Cancer, Imperial College, London, UK., Moderau N; Department of Surgery and Cancer, Imperial College, London, UK., Poyia F; Department of Surgery and Cancer, Imperial College, London, UK., Schwartzberg LS; West Cancer Center, The University of Tennessee, Memphis, USA., Tabassum N; Department of Surgery and Cancer, Imperial College, London, UK., Wen J; Department of Surgery and Cancer, Imperial College, London, UK., Krell J; Department of Surgery and Cancer, Imperial College, London, UK., Stebbing J; Department of Surgery and Cancer, Imperial College, London, UK.
Jazyk:	angličtina
Zdroj:	Oncotarget [Oncotarget] 2018 Feb 24; Vol. 9 (25), pp. 17589-17596. Date of Electronic Publication: 2018 Feb 24 (Print Publication: 2018).
DOI:	10.18632/oncotarget.24564
Abstrakt:	We used data obtained by Caris Life Sciences, to evaluate the benefits of tailoring treatments for a breast carcinoma cohort by using tumor molecular profiles to inform decisions. Data for 92 breast cancer patients from the commercial Caris Molecular Intelligence database was retrospectively divided into two groups, so that the first always followed treatment recommendations, whereas in the second group all patients received at least one drug after profiling that was predicted to lack benefit. The biomarker and drug associations were based on tests including fluorescent in situ hybridization and DNA sequencing, although immunohistochemistry was the main test used. Patients whose drugs matched those recommended according to their tumor profile had an average overall survival of 667 days, compared to 510 days for patients that did not (P=0.0316). In the matched treatment group, 26% of patients were deceased by the last time of monitoring, whereas this was 41% in the unmatched group (P=0.1257). We therefore confirm the ability of tumor molecular profiling to improve survival of breast cancer patients. Immunohistochemistry biomarkers for the androgen, estrogen and progesterone receptors were found to be prognostic for survival. Competing Interests: CONFLICTS OF INTEREST Authors received no funding or honoraria for this publication. The data were analysed independently of Caris. Lee S. Schwartzberg is on the scientific advisory board of Caris Life Sciences.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu